Abstract
Mercaptopurine has been used in continuing treatment of childhood acute lymphoblastic leukaemia since the mid 1950s. Recent advances in the understanding of thiopurine pharmacology indicated that thioguanine (TG) might be more effective than mercaptopurine (MP). The US and UK cooperative groups began randomised thiopurine trials and agreed prospectively to a meta-analysis. All randomised trials of TG versus MP were sought, and data on individual patients were analysed by standard methods. Combining three trials (from US, UK and Germany), the overall event-free survival (EFS) was not significantly improved with TG (odds ratio (OR)=0.89; 95% confidence interval 0.78–1.03). Apparent differences in results between trials may be partly explained by the different types of patients studied. The larger treatment effect reported in males in the US trial was confirmed in the other trials. There was heterogeneity between sex/age subgroups (P=0.001), with significant EFS benefit of TG only observed for males aged <10 years old (OR=0.70; 0.58–0.84), although this did not result in a significant difference in overall survival (OR=0.83; 0.62–1.10). Additional toxicity occurs with TG. Mercaptopurine remains the standard thiopurine of choice, but further study of TG may be warranted to determine whether it could benefit particular subgroups.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Harms DO, Gobel U, Spaar HJ, Graubner UB, Jorch N, Gutjahr P et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003; 102: 2736–2740.
Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006; 368: 1339–1348.
Stork LC, Sather H, Hutchinson HJ, Broxson EH, Matloub Y, Yanofsky R et al. Comparison of mercaptopurine (MP) with thioguanine (TG) and IT methotrexate (ITM) with IT ‘Triples’ (ITT) in children with SR-ALL: results of CCG-1952. Blood 2002; 100: 156a, A585.
Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood 2010; 115: 2740–2748.
Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Br J Haematol 2009; 145: 376–388.
Higgins JP, Thompson SG, Deeks JJ, Altman DG . Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
Lennard L, Lilleyman JS . Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989; 7: 1816–1823.
Lilleyman JS, Lennard L, Rees CA, Morgan G, Maddocks JL . Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization. Br J Cancer 1984; 49: 703–707.
Acknowledgements
The work was funded by a grant from the Kay Kendall Leukaemia Fund (KKL293) with additional support from the Cancer Research UK and Medical Research Council. The secretariat for this work was at CTSU, Oxford University (T Elphinstone, V Evans, L Gettins, C Hicks, L MacKinnon, P Morris, S Richards, R Wade, C Wise).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Escherich, G., Richards, S., Stork, L. et al. Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia 25, 953–959 (2011). https://doi.org/10.1038/leu.2011.37
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.37
Keywords
This article is cited by
-
Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations
Leukemia (2022)
-
DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia
Leukemia (2022)
-
DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis
Leukemia (2022)
-
Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol
BMC Cancer (2022)